These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 23265768)
1. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Malik A; Shoukier M; Garcia-Manero G; Wierda W; Cortes J; Bickel S; Keating MJ; Estrov Z Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):292-5. PubMed ID: 23265768 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Blum KA; Liu Z; Lucas DM; Chen P; Xie Z; Baiocchi R; Benson DM; Devine SM; Jones J; Andritsos L; Flynn J; Plass C; Marcucci G; Chan KK; Grever MR; Byrd JC Br J Haematol; 2010 Jul; 150(2):189-95. PubMed ID: 20456354 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A; Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330 [TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704 [TBL] [Abstract][Full Text] [Related]
7. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774 [TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Fenchel K; Bergmann L; Wijermans P; Engert A; Pralle H; Mitrou PS; Diehl V; Hoelzer D Leuk Lymphoma; 1995 Aug; 18(5-6):485-92. PubMed ID: 8528057 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141 [TBL] [Abstract][Full Text] [Related]
13. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420 [TBL] [Abstract][Full Text] [Related]
14. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816 [TBL] [Abstract][Full Text] [Related]
16. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response. Angelopoulou MA; Poziopoulos C; Boussiotis VA; Kontopidou F; Pangalis GA Leuk Lymphoma; 1996 Apr; 21(3-4):321-4. PubMed ID: 8726414 [TBL] [Abstract][Full Text] [Related]
17. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133 [TBL] [Abstract][Full Text] [Related]
18. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544 [TBL] [Abstract][Full Text] [Related]
19. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Hallek M; Schmitt B; Wilhelm M; Busch R; Kröber A; Fostitsch HP; Sezer O; Herold M; Knauf W; Wendtner CM; Kuse R; Freund M; Franke A; Schriever F; Nerl C; Döhner H; Thiel E; Hiddemann W; Brittinger G; Emmerich B; Br J Haematol; 2001 Aug; 114(2):342-8. PubMed ID: 11529853 [TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]